Patent Application
20080261895
Venlafaxine, chemically named 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol, has been shown to be a potent inhibitor of monoamine neurotransmitter uptake, a mechanism associated with clinical antidepressant activity. Due to its novel structure, venlafaxine has a mechanism of action unrelated to other available antidepressants, such as the tricyclic antidepressants desipramine, nostriptyline, protriptyline, imipramine, amitryptyline, trimipramine and doxepin.
It is believed that venlafaxine's mechanism of action is related to potent inhibition of the uptake of the monoamine neurotransmitters serotonin and norepinephrine. To a lesser degree, venlafaxine also inhibits dopamine reuptake, but it has no inhibitory activity on monoamine oxidase. O-desmethylvenlafaxine, venlafaxine's major metabolite in humans, exhibits a similar pharmacologic profile. Venlafaxine's ability to inhibit norepinephrine and serotonin (5-HT) uptake has been predicted to have an efficacy which rivals or surpasses that of tricyclic antidepressants. Montgomery, S. A., Venlafaxine: A New Dimension in Antidepressant Pharmacotherapy, J. Clin. Psychiatry, 54(3):119 (1993).
In contrast to classical tricyclic antidepressant drugs, venlafaxine has virtually no affinity for muscarinic, histaminergic or adrenergic receptors in vitro. Pharmacologic activity at these receptors is associated with the various anticholinergic, sedative and cardiovascular effects seen with the tricyclic antidepressant drugs.
Venlafaxine is disclosed in U.S. Pat. No. 4,535,186 (Husbands et al.) and has been previously reported to be useful as an antidepressant.
O-desmethylvenlafaxine (“DV”), chemically named 1-[2-(dimethylamino)-1-(4-phenol) ethyl]-cyclohexanol, is a major metabolite of venlafaxine and has been shown to inhibit norepinephrine and serotonin uptake. Klamerus, K. J. et al., “Introduction of the Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O-Desmethyl Metabolite”, J. Clin. Pharmacol. 32:716-724 (1992). A particularly useful novel salt form of O-desmethyl venlafaxine with unique properties, O-desmethylvenlafaxine succinate (“DVS”), was disclosed in U.S. Pat. No. 6,673,838 (Hadfield et al.).
Previously, only a limited understanding of the metabolites formed from venlafaxine and O-desmethylvenlafaxine, whether in their free base or salt forms, existed. Therefore, while some information on the metabolic products of venlafaxine was known, see Howell, S. R. et al., “Metabolic Disposition of 14C-Venlafaxine in Mouse, Rat, Dog, Rhesus Monkey and Man,” Xenobiotica 23(4):349359 (1993), the prior art lacked a complete understanding of all of the metabolic products and the activities therefore. The inventors now have a more complete understanding of the metabolites produced and the end uses therefor.
The present invention provides novel isolated compounds that were characterized as metabolites or derivatives of DV, their corresponding pharmaceutical compositions, and methods of treatment.
Specifically, the present invention includes an isolated Hydroxy-DV metabolite or derivative of the formula
wherein
a hydroxy group is attached to one 2-position (ortho-position) or 3-position (meta-position) carbon on the cyclohexyl ring as shown by the dashed-line box;
and pharmaceutically acceptable salts thereof. In one embodiment, the isolated DV metabolite is a 2-Hydroxy-DV metabolite. In another embodiment, the isolated DV metabolite is a 3-Hydroxy-DV metabolite.
The invention also includes an isolated Hydroxy-DV glucuronide metabolite or derivative of the formula
wherein a hydroxy group is attached to one 2-position (ortho), 3-position (meta), or 4-position (para) carbon on the cyclohexyl ring as shown by the dashed-line box;
and pharmaceutically acceptable salts thereof. In one embodiment, the isolated DV metabolite is a 2-Hydroxy-DV glucuronide metabolite. In another embodiment, the isolated DV metabolite is a 3-Hydroxy-DV glucuronide metabolite. In a third embodiment, the isolated DV metabolite is a 4-Hydroxy-DV glucuronide metabolite.
The invention further includes an isolated N-Oxide DV metabolite or derivative of the formula
and pharmaceutically acceptable salts thereof.
The invention further includes isolated Benzyl Hydroxy-DV metabolites or derivatives of the formula
wherein a hydroxy group is attached to one 2-position or 3-position carbon on the benzyl;
and pharmaceutically acceptable salts thereof. In one embodiment, the isolated DV metabolite is 2-Benzyl Hydroxy-DV. In another embodiment, the isolated DV metabolite is 3-Benzyl Hydrozy-DV.
Likewise, the invention includes pharmaceutical compositions comprising any of the metabolites or derivatives of the invention in combination with a pharmaceutically acceptable carrier or excipient. It includes a method of treating at least one central nervous system disorder in a mammal comprising providing to a mammal in need thereof an effective amount of the compounds of the invention.
A. Isolated DV Metabolites and Derivatives
The present invention relates to newly identified metabolites and derivatives of DV expected to have beneficial properties. While some of the compounds are natural metabolites (those produced by enzymatic and other reactions in the body and in models therefor), others are related structures (derivatives) that are expected to exhibit substantially similar activity.
As shown in
DV metabolites hydroxylated at any of the 2-, 3-, or 4-positions on the cyclohexyl ring may be glucuronidated to form cyclohexyl hydroxy-DV glucuronides, shown in
This application provides figures showing the structure of each compound, information on the compound as a metabolic product of DV, isolation, and/or synthesis, as well as expected activity for each compound.
1. Compounds Characterized from In Vivo Rat Experiments
The metabolism of DVS was investigated in rats following a single oral administration of 20 mg/kg (measured as amount of free base). DVS was extensively and rapidly metabolized in the rat, primarily to O-desmethylvenlafaxine O-glucuronide (DV glucuronide). DV glucuronide was the predominant drug-related compound in all plasma and urine samples analyzed.
M1-M6, six distinct hydroxyl-metabolites, were detected by LC/MS and in some samples by radiochromatography. In these metabolites, the hydroxyl group attaches at the 2-, 3-, and 4-positions on the cyclohexanol ring, yielding six distinct compounds, M1-M6. The glucuronides of these hydroxy DV metabolites were not observed in rats. N-oxide DV was observed via LC/MS in rat plasma, urine, and feces. Additional metabolites were also observed.
2. Compounds Characterized from In Vivo Dog Experiments
The metabolism of DVS in beagle dogs was determined following a single oral administration of 30 mg/kg (free base). DVS was extensively and rapidly metabolized in dogs. DV glucuronide was the most abundant metabolite detected by radiochromatography of urine and plasma samples.
Compounds M1-M6 were observed via LC/MS in plasma, urine, and feces. Compounds M11 and M12 were observed in urine (via radiochromatography and LC/MS). N-Oxide DV compounds were observed in plasma (via LC/MS), urine (via LC/MS), and feces (via radiochromatography and LC/MS). Additional metabolites were also observed.
In summary, DVS was rapidly and extensively metabolized to a number of metabolites in dogs. The most abundant metabolite detected was DV O-glucuronide. The metabolites observed in the current study were similar to those observed in rat plasma, urine, and feces following oral administration, with a greater number of metabolites being observed in beagle dogs.
B. Activity
The compounds of the present invention were detected as metabolites or derivatives of DVS, and are believed to exhibit a type of activity similar to that of venlafaxine and DVS. The hydroxy-DV glucuronides are believed to act as pro drugs, with the glucuronide being cleaved in vivo prior to activity. Cleavage of the glucuronide may occur via either the action of β-glucuronidase, which may be particularly active in the gastrointestinal tract, or under acidic conditions, such as those in the stomach. The hydroxyl-DV and N-oxide DV compounds are expected to be active in their current form. The compounds of the present invention may be tested for specific biological activities using receptor assay binding studies and in vivo metabolic and efficacy studies, which are well known in the art. See Example 5.
C. Synthesis
1. Syntheses of Free Base Compounds
The compounds of the present invention can be prepared using the methods described below, together with synthetic methods known in the synthetic organic arts or variations of these methods by one skilled in the art. See, generally, Comprehensive Organic Synthesis, “Selectivity, Strategy & Efficiency in Modern Organic Chemistry”, ed., I. Fleming, Pergamon Press, New York (1991); Comprehensive Organic Chemistry, “The Synthesis and Reactions of Organic Compounds”, ed. J. F. Stoddard, Pergamon Press, New York (1979). Suitable methods include, but are not limited to, those outlined below.
In the second step, an acidic solution of a protected 2-hydroxy cyclohexanone (protected at the hydroxy) is added under appropriate using lithium diisopropylamide as a reagent. Suitable protecting groups are known in the art, and include benzyl-, trimethylsilyl-, and tert-butyl-dimethylsilyl-groups.
In the third step, the ketone is removed using lithium aluminum hydroxide. Alternatively, the ketone may be removed using sodium borohydride. The final step shows removal of the protecting groups. A similar method can be used for synthesis of the 3-hydroxy DV compounds, using the appropriate protected 3-substituted cyclohexanone. In addition, this method can be used to prepare 4-hydroxy DV compounds using an appropriate protected 4-substituted cyclohexanone.
Benzyl hydroxy DV compounds can be prepared following the procedures outlined in Yardley, J P et al., “2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine Derivatives: Synthesis and Antidepressant Activity,” Journal of Medicinal Chemistry 33(10): 2899-905 (1990). One of skill in the art would be able to adapt the synthetic schemes for the preparation of other structures depicted in Yardley to synthesize both the 2-benzyl hydroxy DV compounds and the 3-hydroxy DV compounds in light of the present discovery that such compounds are desired. For example, starting with (3,4-bis-benzyloxy-phenyl)-acetic acid, a 3-substituted benzyl hydroxy DV can be prepared as shown in
2. Syntheses of Salts
The compounds of the present invention can have utility in both their free base and salt forms. The pharmaceutically acceptable acid addition salts of the basic compounds of this invention are formed conventionally by reaction of the free base with an equivalent amount of any acid which forms a non-toxic salt. Illustrative acids are either inorganic or organic, including hydrochloric, hydrobromic, fumaric, maleic, succinic, sulfuric, phosphoric, tartaric, acetic, citric, oxalic, benzenesulfonic, benzoic, camphorsulfonic, ethenesulfonic, gluconic, glutamic, isethionic, lactic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, p-toluenesulfonic and similar acids. For parenteral administration, water soluble salts may be used, although either the free base or the pharmaceutically acceptable salts are applicable for oral or parenteral administration of the compounds of this invention.
3. Stereochemistry
The compounds of the present invention exist as enantiomers and this invention includes racemic mixtures as well as stereoisomerically pure forms of the compounds of the invention (both the R-enantiomer and the S-enantiomer), unless otherwise indicated.
D. Isolation
Alternatively, the compounds of the present invention can be isolated from plasma, urine, or fecal samples containing the compound, or from an in vitro system containing the compound using techniques known in the art. Specifically, the compounds may be isolated using preparatory-scale HPLC (prep-HPLC) under conditions that lead to a separation of the individual metabolites, for example, using a linear gradient of two mobile phases, A and B, wherein mobile phase A may be 10 mM ammonium acetate, pH 5.5, and mobile phase B may be acetonitrile, at a flow rate leading to separation, as described in Examples 1-2.
Such isolated compounds may be in purified form or may be in substantially purified form, meaning that they are removed from their natural environment. Substantially pure compounds include compounds that are 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 85%, 80%, 75%, 70%, 65% pure.
E. Pharmaceutical Dosage Forms
Pharmaceutical compositions containing the compounds of this invention represent an additional aspect of this invention. The active ingredients can be compounded into any of the usual oral dosage forms including tablets, capsules and liquid preparations such as elixirs and suspensions containing various coloring, flavoring, stabilizing and flavor masking substances. For compounding oral dosage forms, the active ingredient can be mixed with various conventional tabletting materials such as starch, calcium carbonate, lactose, sucrose and dicalcium phosphate to aid the tabletting or capsulating process. Magnesium stearate, as an additive, provides a useful lubricant function when desired. The active ingredients can be dissolved or suspended in a pharmaceutically acceptable sterile liquid carrier, such as sterile water, sterile organic solvent or a mixture of both. A liquid carrier may be one suitable for parenteral injection. Where the active ingredient is sufficiently soluble it can be dissolved in normal saline as a carrier; if it is too insoluble for this it can often be dissolved in a suitable organic solvent, for instance aqueous propylene glycol or polyethylene glycol solutions. Aqueous propylene glycol containing from 10 to 75% of the glycol by weight is generally suitable. In other instances other compositions can be made by dispersing the finely-divided active ingredient in aqueous starch or sodium carboxymethyl cellulose solution, or in a suitable oil, for instance arachis oil. Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by intramuscular, intraperitoneal or subcutaneous injection.
The compounds of the present invention can be combined with a pharmaceutical carrier or excipient (e.g., pharmaceutically acceptable carriers and excipients) according to conventional pharmaceutical compounding technique to form a pharmaceutical composition or dosage form. Suitable pharmaceutically acceptable carriers and excipients include, but are not limited to, those described in Remington's, The Science and Practice of Pharmacy, (Gennaro, A. R., ed., 19th edition, 1995, Mack Pub. Co.). The phrase “pharmaceutically acceptable” refers to additives or compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to an animal, such as a mammal (e.g., a human). For oral liquid pharmaceutical compositions, pharmaceutical carriers and excipients can include, but are not limited to water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like. Oral solid pharmaceutical compositions may include, but are not limited to starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders and disintegrating agents. The pharmaceutical composition and dosage form may also include venlafaxine, O-desmethylvenlafaxine, or salts thereof as discussed above.
Dosage forms include, but are not limited to tablets, troches, lozenges, dispersions, suspensions, suppositories, ointments, cataplasms, pastes, powders, creams, solutions, capsules (including encapsulated spheroids), and patches. The dosage forms may also include immediate release as well as formulations adapted for controlled, sustained, extended, or delayed release. Tablets and spheroids may be coated by standard aqueous and nonaqueous techniques as required.
Pharmaceutical composition may be in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit doses containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example, packeted powders or vials or ampoules. The unit dosage form can be a capsule, cachet or tablet itself, or it can be the appropriate number of any of these in package form. The quantity of the active ingredient in a unit dose of composition may be varied or adjusted according to the particular need and the activity of the active ingredient.
A. Diseases that may be treated
The methods of the present invention involve administering to a mammal in need thereof an effective amount of one or more of the compounds of the present invention.
The compounds of the present invention are believed to have activity of a type similar to that of venlafaxine and O-desmethylvenlafaxine. The hydroxy-DV glucuronides may act as a pro drugs, losing the glucuronide appendage in vivo and forming the corresponding hydroxyl-DV compounds. Cleavage of the glucuronide may occur via either the action of β-glucuronidase, which may be particularly active in the gastrointestinal tract, or under acidic conditions, such as those in the stomach. The remaining compounds are expected to have activity in their current forms.
As described in Reviews in Contemporary Pharmacology, Volume 9(5) page 293-302 (1998), O-desmethyl-venlafaxine has the pharmacological profile shown in Table 1.
Thus, compounds, compositions and methods of the present invention may be used to treat patients suffering from or susceptible to at least one central nervous system disorder including, but not limited to depression (including but not limited to major depressive disorder, bipolar disorder and dysthymia), fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction (including premature ejaculation), borderline personality disorder, chronic fatigue syndrome, incontinence (including fecal incontinence, overflow incontinence, passive incontinence, reflex incontinence, stress urinary incontinence, urge incontinence, urinary exertional incontinence and urinary incontinence), pain (including but not limited to migraine, chronic back pain, phantom limb pain, central pain, neuropathic pain such as diabetic neuropathy, and postherpetic neuropathy), Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, epilepsy, and others. Compounds and compositions of the present invention can also be used for preventing relapse or recurrence of depression, including continuing treatment of a patient who previously had depression and is in a state of remission; to treat cognitive impairment; for the inducement of cognitive enhancement and/or enhanced mood in patient suffering from senile dementia, Alzheimer's disease, memory loss, amnesia and amnesia syndrome; and in regimens for cessation of smoking or other tobacco uses. Additionally, compounds and compositions of the present invention can be used for treating hypothalamic amenorrhea in depressed and non-depressed human females.
B. Administration and Dosage
This invention provides methods of treating, preventing, inhibiting or alleviating each of the maladies listed above in a mammal, including a human, the methods comprising administering an effective amount of a compound of the invention to a mammal in need thereof. An effective amount is an amount sufficient to prevent, inhibit, or alleviate one or more symptoms of the aforementioned conditions.
The dosage amount useful to treat, prevent, inhibit or alleviate each of the aforementioned conditions will vary with the severity of the condition to be treated and the route of administration. The dose and dose frequency will also vary according to age, body weight, response and past medical history of the individual human patient. In general, the recommended daily dose range for the conditions described herein include from 10 mg to 1000 mg per day of a compound of the present invention. Other appropriate dosages include from 50 mg to 800 mg per day, from 75 mg to 600 mg per day, from 100 mg to 500 mg per day, and from 150 mg to 300 mg per day, and 200 mg per day. Specific dosages include all of the endpoints listed above. Dosage is described in terms of the free base, and not in terms of any particular pharmaceutically acceptable salt. In managing the patient, the therapy may be initiated at a lower dose and increased if necessary. Dosages for non-human patients can be adjusted accordingly by one skilled in the art.
The compounds of the present invention may also be provided in combination with venlafaxine, O-desmethylvenlafaxine, DVS, or other pharmaceutically acceptable salts thereof. The compounds of the present invention may also be provided with other known psychiatrically-active compounds, such as other antidepressants or antianxiety drugs, hormonal treatments, pain medications, and other therapies.
Any suitable route of administration can be employed for providing the patient with an effective amount of the compounds of interest. For example, oral, mucosal (e.g. nasal, sublingual, buccal, rectal or vaginal), parental (e.g. intravenous or intramuscular), transdermal, and subcutaneous routes can be employed.
The following examples are illustrative but are not meant to be limiting of the present invention.
Six hydroxy DV compounds and N-oxide DV compounds, as well as other compounds, were detected in the metabolic profiles for [14C]DVS in urine, feces, and plasma following a single oral gavage dose in male and female rats as described below.
Radiolabeled [14C]DVS (Batch #CFQ13003, [cyclohexyl-1-14C]DVS) was supplied by Amersham Biosciences (Buckinghamshire, UK). Unlabeled DVS (Batch RB1636; free base 65.2%) was received from Wyeth Research, Rouses Point, N.Y. The average molecular weight of DVS is 381.5, with O-desmethylvenlafaxine, accounting for 69.0% by weight. The specific activity of [14C]DVS (bulk drug) was 144 μCi/mg (209 μCi/mg for the free base) and the radiopurity of the free base was 99.3%, as determined by HPLC using radiometric detection.
Water for preparation of the oral dosing solution was obtained from EM Science (Gibbstown, N.J.). Methylcellulose and polysorbate 80 were received from Sigma Chemical Co. (St. Louis, Mo.) and Mallinckrodt Baker (Phillipsburg, N.J.), respectively. The liquid scintillation cocktail used in counting the radioactivity in urine and plasma samples, fecal homogenate extracts and the dosing solution aliquots was Ultima Gold™ (Perkin Elmer, Wellesley, Mass.).
A model 307 Tri-Carb Sample Oxidizer, equipped with an Oximate-80 Robotic Automatic Sampler (Perkin Elmer), was used for combustion of blood and fecal samples. PermaFluor® E+ liquid scintillation cocktail (Perkin Elmer), Carbosorb® E (Perkin Elmer) carbon dioxide absorber and HPLC grade water were used to trap radioactive carbon dioxide generated by combustion of the samples in the oxidizer. Fecal homogenates and blood samples were transferred to combusto-cones and cover pads (Perkin Elmer) for combustion.
Sprague Dawley rats (12 male and 6 female), weighing between 0.311 and 0.345 kg for males and between 0.263 and 0.311 kg for females at the time of dosing, were used. Animals were given food and water ad libitum. For ease of reporting, the animals were designated numbers 001M through 012M for the male rats and 001F through 006F for the female rats. Three animals from the last time point, for each sex, were housed individually in metabolism cages for the collection of urine and feces. The other animals were housed individually in standard cages.
The oral dosing solution was prepared by combining 86.4 mL of 3.0 mg/mL (2.0 mg/mL, free base) unlabeled DVS solution with 3.6 mL of 4.3 mg/mL (3.0 mg/mL free base) [14C]DVS solution. Solutions were prepared in 0.25% polysorbate 80, 0.5% methylcellulose in water. The radiochemical purity, specific activity and concentration of [14C]DVS (bulk drug and dosing solution) were determined using HPLC with radiometric detection. Aliquots of the dosing solution were taken pre-, mid-, and post-dose for the determination of specific activity and radioactivity concentrations of dosing solution.
The target dose for each animal was 30 mg/kg (free base; 3.0 mg/mL, 10 mL/kg, 250 μCi/kg) [14C]O-desmethylvenlafaxine via oral gavage.
Whole blood (approximately 5 mL) was collected by cardiac puncture into heparinized tubes at the appropriate time points (1, 4, 8, and 24 hours for male rats, and 1 and 8 hours for female rats, N=3 for each sex at each time point). Triplicate aliquots (200 μL) of whole blood were placed into combusto-cones, weighed and allowed to air dry. These samples were oxidized. The remaining blood was centrifuged at 5000×g and 4° C. for 10 minutes (Model Legend RT centrifuge, Sorvall). The resulting plasma was transferred to fresh tubes and triplicate aliquots (100 μL) were analyzed for radioactivity content. The remaining plasma was stored at −70° C. until metabolite analysis.
Urine and feces were collected separately on dry ice from three animals per sex. Collections were from 0-8 and 8-24 hours for male rats and 0-8 hours for female rats. Fecal samples were homogenized in approximately five volumes (v/w) of water. Aliquots of approximately 0.4 grams of the homogenate were placed into combusto-cones, weighed and allowed to air dry. These samples were then oxidized. The remaining urine samples and fecal homogenates were stored at −70° C. until metabolite analysis.
Blood samples and fecal homogenates were oxidized in a Model 307 Tri-Carb sample oxidizer, using Carbosorb® E (6 mL) as trapping agent and PermaFluor® E+ (10 mL) as scintillant. Oxidation efficiency was determined by oxidation of C-Spec-Chec (Perkin Elmer), a standard of known radioactivity, and determined to be 98.7%. The background reading (average of control blood or fecal samples) was subtracted from each sample reading. Aliquots of urine and plasma were analyzed directly following the addition of 10 mL of Ultima Gold™ scintillation fluid.
All radioactivity determinations were made using a Tri-Carb Model 3100TR liquid scintillation counter (Perkin Elmer) with an Ultima Gold™ or toluene standard curve. Counts per minute (CPM) were converted to disintegrations per minute (DPM) by use of external standards of known radioactivity. The quench of each standard was determined by the transformed spectral index of an external radioactive standard (tSIE). The lower limits of detection were defined as twice background.
Plasma samples collected at 1, 4 and 8 hours post-dose were analyzed for metabolite profiles. Aliquots of 0.5 mL plasma were mixed with an equal volume of acetonitrile, placed on ice for approximately 10 minutes, and then centrifuged at 3500 rpm and 4° C. in a Sorvall Super 21 centrifuge for 10 minutes. The supernatant fluid was transferred to a clean tube. The supernatant was analyzed for radioactivity. The supernatant was concentrated under a stream of nitrogen in a Turbo Vap (Zymark, Hopinkton, Mass.) to remove the acetonitrile. An aliquot of the aqueous residue was analyzed by HPLC for metabolite profiling. Selected samples were also analyzed by LC/MS to characterize the radioactive peaks.
The stability of [14C]DVS in rat plasma was determined. [14C]DVS (0.01 mg/mL, final concentration) was added to control rat plasma and incubated in a shaking water bath set to 37° C. Aliquots (0.5 mL) were removed at 0, 1, 4, 8 and 24 hours. Samples were extracted as described above and radiopurity assayed by HPLC analysis.
All urine samples were analyzed for metabolite profiles. Aliquots of 0.5 mL urine were centrifuged at 3500 rpm and 4° C. in a Sorvall Super 21 centrifuge for 10 minutes. The supernatant was transferred to a fresh tube and analyzed for radioactivity content and by HPLC for profiling. Selected samples were also analyzed by LC/MS to characterize the radioactive peaks.
The stability of [14C]DVS in rat urine was determined. [14C]DVS (0.13 mg/mL, final concentration) was added to control rat urine and incubated in a shaking water bath set to 37° C. Aliquots (0.5 mL) were removed at 0, 1, 4, 8 and 24 hours. Samples were extracted as described above and radiopurity assayed by HPLC analysis.
Fecal homogenates collected from male rats between 8 and 24 hours post-dose were analyzed for metabolite profiles. Aliquots of approximately 1 gram of fecal homogenate were centrifuged at 3500 rpm and 4° C. in a Sorvall Super 21 centrifuge for 10 minutes. The supernatant was transferred to a clean tube. The residue was re-suspended with 1 mL of water:acetonitrile (1:1, v:v) and centrifuged as described above. The resulting supernatant was combined with the original supernatant and the residue re-suspended with 1 mL of acetonitrile. The suspension was centrifuged as described above, and the supernatants were combined and analyzed for radioactivity. The supernatants were then concentrated under a stream of nitrogen in a Turbo Vap to remove the acetonitrile. An aliquot of the aqueous residue was analyzed by HPLC for profiling. Selected samples were also analyzed by LC/MS to characterize the radioactive peaks.
Chromatographic analyses were performed with a Waters Alliance model 2690 HPLC system (Waters Corp., Milford, Mass.). It was equipped with a built-in autosampler and was in-line with a model 2487 tunable UV detector, set to monitor 225 nm, and a FloOne β Model 525 radioactivity flow detector (Perkin Elmer) with a 250 μL LQTR flow cell. The flow rate of Ultima Flow M scintillation fluid was 1 mL/min, providing a mixing ratio of scintillation cocktail to mobile phase of 5:1. Separation of the metabolite peaks was accomplished on a Phenomenex Luna C18(2) column, 150×2.0 mm, 5 micron (Phenomenex, Torrance, Calif.), using a linear gradient of two mobile phases, A and B. Mobile phase A was 10 mM ammonium acetate, pH 6.0, and mobile phase B was acetonitrile. The flow rate was 0.2 mL/min. The mobile phase was delivered as shown in Table 2.
An Agilent Model 1100 HPLC system (Agilent Technologies, Wilmington, Del.) including an autosampler and diode array UV detector was used for LC/MS analysis. The UV detector was set to monitor 200 to 400 nm. Separations were accomplished on a 5 micron Phenomenex Luna C18(2) column, 150×2 mm (Phenomenex). The column temperature was 25° C. The mobile phases and gradient program were as follows.
The mass spectrometer used for metabolite characterization was a Micromass Q-TOF-2 quadrupole time-of-flight hybrid mass spectrometer (Micromass, Inc., Beverly, Mass.). The mass spectrometer was equipped with an electrospray ionization (ESI) interface and operated in the positive ionization mode. Settings for the mass spectrometer are listed in Table 3.
FloOne analytical software (version 3.65, Packard BioScience, Boston, Mass.) was utilized for data collection and analysis of the radioactive peaks. The computer program Microsoft Excel®97 was used to calculate means and standard deviations. MassLynx software (version 3.5) was used to analyze LC/MS data.
The radiochemical purity and specific activity of [14C]DVS (bulk compound), determined by HPLC with radiometric detection, were 99.3% and 209 μCi/mg (free base), respectively. The concentration, radiopurity and specific activity of [14C]O-desmethylvenlafaxine in the dosing solution were 2.05 mg/mL, 97.8% and 11.7 μCi/mg, respectively. Pre-, mid- and post-dose aliquots of the dosing solution had similar concentrations and purities. The mean administered dose of [14C]DVS was 19.9±0.24 mg/kg (free base). This dose deviated from the target dose of 30 mg/kg (free base) because the original weighing for the dose preparation did not take into account that DVS is the succinate salt of O-desmethylvenlafaxine (free base).
[14C]DVS was stable at 37° C. for up to 24 hours in both control rat urine and control rat plasma. The radiopurity of [14C]DVS in rat plasma was greater than 98.9% at all time points, while in rat urine the radiopurity was greater than 99.5% at all time points.
The concentrations of radioactivity in blood and plasma, and the blood to plasma partitioning are shown in Table 4. There were no significant differences in the concentration of radioactivity detected in blood or plasma between male and female rats. The mean plasma concentrations of total radioactivity in male rats were 11.0, 1.48, 0.89 and 0.07 μg equivalents/mL at 1, 4, 8 and 24 hour post-dose, respectively. For female rats, the mean plasma concentrations of total radioactivity were 9.90 and 0.92 μg equivalents/mL at 1 and 8 hour post-dose, respectively. At the 1, 4 and 8 hour time points, the blood to plasma ratio for radioactivity ranged between 0.59 and 0.67 in both sexes, while at the 24 hour time point the ratio was 0.99 in male rats.
The average extraction efficiency of radioactivity from plasma was 98.7±13.0% (data not shown). A representative radiochromatogram of rat plasma collected from male rats 1 hour post-dose is shown in
Additional minor metabolites, not present in the radiochromatogram, were detected and characterized by LC/MS in rat plasma (Table 5). These metabolites included N-oxide DV, N,O-didesmethylvenlafaxine (M10), N,O-didesmethylvenlafaxine O-glucuronide (M13).
P, U, F
P, U, F
aP: plasma; U: urine; F: feces. Bold face type indicates that the metabolite was also detected by radiochromatography.
bN-oxide was not detected in fecal samples by LC/MS, but was observed using radiochromatography.
Urine was the predominant route of excretion, with greater than 50% of the radioactive dose recovered in urine samples within the first 8 hours post-dose and 85% recovered within 24 hours post-dose. The radioactivity concentrations detected in urine are shown in Table 6, as are the percent distribution of the radioactivity following radiochromatographic analysis. A representative radiochromatogram of rat urine collected 0-8 hours post-dose is shown in
aValues are expressed as percent of total peaks detected by radiochromatography.
Additional minor metabolites, not present in the radiochromatogram, were detected and characterized by LC/MS in urine (Table 5). These metabolites included M3, M4, M5, M6, N-oxide DV, N,O-didesmethylvenlafaxine (M10), N,O-didesmethylvenlafaxine O-glucuronide (M13).
The efficiency of extraction of radioactivity from the 8-24 hour fecal samples prior to radiochromatographic analysis was 74.8±1.9% (data not shown). Only a small percentage of the radioactive dose (approximately 10%) was excreted in feces within 24 hours of dosing. Less than 0.1% of the radioactive dose was excreted in 0-8 hour fecal samples. The percent recovery in feces and the distribution of the radioactivity following radiochromatography analysis from individual rats are shown in Table 7. A representative radiochromatogram of extracted rat feces collected 8-24 hours post-dose is shown in
aValues are expressed as percent of total peaks detected by radiochromatography.
bFecal samples collected from male and female rats from 0-8 hours post-dose contained 0.017 and 0.025% of the radioactive dose, respectively, and were not analyzed by radiochromatography.
Mass spectra were obtained by LC/MS and LC/MS/MS analysis for DVS and its metabolites in rat plasma, urine, and feces. Structural characterization of the DVS metabolites in rat is summarized in Table 5. LC/MS data indicated metabolism of DVS to a glucuronide (M7), N,O-didesmethylvenlafaxine (M10), and hydroxylation products (M1-M6). The mass spectral characterization of these metabolites, DVS, N-oxide DV, and a minor metabolite (M13) is discussed below.
The mass spectral characteristics of a DVS standard were examined for comparison with metabolites. In the LC/MS spectrum of DVS, a protonated molecular ion, [M+H]+ was observed at m/z 264.
Metabolites M1 to M6 produced a [M+H]+ at m/z 280, which was 16 Da larger than DVS and suggested hydroxylation or N-oxidation.
Metabolite M7 (O-desmethylvenlafaxine O-glucuronide, DV glucuronide)
The [M+H]+ for this metabolite was observed at m/z 440, which indicated a molecular weight of 439.
The [M+H]+ for M1 was observed at m/z 250.
The [M+H]+ for this metabolite was observed at m/z 426, which indicated a molecular weight of 425.
The [M+H]+ for this DVS related component was observed at m/z 280, which indicated hydroxylation or N-oxidation.
(2 or 3)-Hydroxy DV compounds, hydroxy DV glucuronides, N-oxide DV compounds, as well as other compounds, and a benzyl hydroxy compound were detected in the metabolic profiles for [14C]DVS in urine, feces, and plasma following a single oral gavage dose in male beagle dogs as described below.
Radiolabeled [14C]DVS (Batch #CFQ13003, [cyclohexyl-1-14C]DVS) was supplied by Amersham Biosciences (Buckinghamshire, UK). Unlabeled DVS (Batch RB1636; free base 65.2%) was received from Wyeth Research, Rouses Point, N.Y. The average molecular weight of DVS is 381.5, with the free base, O-desmethylvenlafaxine, accounting for 69.0% by weight. The specific activity of [14C]DVS (bulk drug) was 144 μCi/mg (209 μCi/mg for the free base) and the radiopurity of the free base was 99.3%, as determined by HPLC using radiometric detection.
Water for preparation of the oral dosing solution was obtained from EM Science (Gibbstown, N.J.). Methylcellulose and polysorbate 80 were received from Sigma Chemical Co. (St. Louis, Mo.) and Mallinckrodt Baker (Phillipsburg, N.J.), respectively. The liquid scintillation cocktail used in counting the radioactivity in urine and plasma samples, fecal homogenate extracts and the dosing solution aliquots was Ultima Gold™ (Perkin Elmer, Wellesley, Mass.). A model 307 Tri-Carb Sample Oxidizer, equipped with an Oximate-80 Robotic Automatic Sampler (Perkin Elmer), was used for combustion of blood and fecal samples. PermaFluor® E+ liquid scintillation cocktail (Perkin Elmer), Carbosorb® E (Perkin Elmer) carbon dioxide absorber and HPLC grade water were used to trap radioactive carbon dioxide generated by combustion of the samples in the oxidizer. Fecal homogenates and blood samples were transferred to combusto-cones and cover pads (Perkin Elmer) for combustion.
Male beagle dogs (n=4), weighing between 14.4 and 16.2 kg at the time of dosing (from an in-house colony), were used. For ease of reporting, the animals were designated numbers 5 through 8. Dose preparation, animal dosing and sample collection were performed at Wyeth Research, Pearl River, N.Y.
The oral dosing solution was prepared by suspending 19.0 mg of [14C]DVS and 4168.3 mg of unlabeled DVS in 270 mL of vehicle (0.25% polysorbate 80, 0.5% methylcellulose in water). The radiochemical purity, specific activity and concentration of [14C]DVS (bulk drug and dosing solution) were determined using HPLC with radiometric detection. Duplicate aliquots of the dosing solution were taken pre-, mid- and post-dose for the determination of specific activity and radioactivity concentrations of the dosing solution.
The target dose for each animal was 30 mg/kg (free base; 10 mg/mL, 3 mL/kg, 30 μCi/kg) [14C]DVS via oral gavage. The target dose was selected because it has been used in previous pharmacokinetic studies. Additionally, this dose, administered subcutaneously, significantly increased the norepinephrine levels in the brains of male Sprague Dawley rats.
Whole blood (approximately 10 mL), collected into heparinized tubes at 1, 4, 8, and 24 hours post-dose (N=4 for each time point), was analyzed. One mL of blood was transferred to a fresh tube to be used for determination of radioactivity concentrations. Plasma was obtained by centrifugation at 4° C. within two hours of blood collection. Plasma and whole blood samples were shipped on dry ice to Wyeth Research, Biotransformation Division (Collegeville, Pa.) for analysis. Triplicate aliquots of whole blood (200 μL) were placed into combusto-cones and allowed to air dry. These samples were then oxidized and radioactivity content determined. Triplicate aliquots (100 μL) of the plasma samples were analyzed for radioactivity content. The remaining plasma was stored at −70° C. until metabolite analysis.
For each dog, urine and feces were collected separately, with urine collected on dry ice and feces collected at room temperature. Collections were from 0-8 and 8-24 hours for urine and 0-24 hours for feces. Urine and fecal samples were shipped on dry ice to Wyeth Research, Biotransformation Division (Collegeville, Pa.) for analysis. Fecal samples were homogenized in approximately five volumes (v/w) of water. Aliquots of approximately 0.2 grams of the homogenate were placed into combusto-cones, weighed and allowed to air dry. These samples were then oxidized and radioactivity content determined. The remaining urine samples and fecal homogenates were stored at −70° C. until metabolite analysis. Blood samples and fecal homogenates were oxidized in a Model 307 Tri-Carb sample oxidizer, using Carbosorb® E (6 mL) as trapping agent and PermaFluor® E+ (10 mL) as scintillant. The background reading (average of control blood or fecal samples) was subtracted from each sample reading. Aliquots of urine and plasma were analyzed directly following the addition of 10 mL of Ultima Gold™ scintillation fluid.
All radioactivity determinations were made using a Tri-Carb Model 3100TR liquid scintillation counter (Packard BioScience, Boston, Mass.) with an Ultima GOl™ or toluene standard curve. Counts per minute (CPM) were converted to disintegrations per minute (DPM) by use of external standards of known radioactivity. The quench of each standard was determined by the transformed spectral index of an external radioactive standard (tSIE). The lower limits of detection were defined as twice background.
Plasma samples collected at 1 and 4 hours post-dose were analyzed for metabolite profiles. Aliquots of 1 mL plasma were mixed with an equal volume of acetonitrile, placed on ice for at least 10 minutes, and then centrifuged at 14000 rpm in an Eppendorf Model 5415C centrifuge for 10 minutes. The supernatant fluid was transferred to a clean tube. The supernatant was analyzed for radioactivity. The supernatant was concentrated under a stream of nitrogen in a Turbo Vap (Zymark, Hopinkton, Mass.) to remove the acetonitrile. An aliquot of the aqueous residue was analyzed by HPLC for profiling. Selected samples were also analyzed by LC/MS to characterize the radioactive peaks.
The stability of [14C]DVS in dog plasma was determined. [14C]DVS (0.012 mg/mL, final concentration) was added to control dog plasma and incubated in a shaking water bath set to 37° C. Duplicate aliquots (1 mL) were removed at 0, 1, 4, 8, and 24 hours. Samples were extracted as described above and radiopurity assayed by HPLC analysis.
Urine samples collected between 8 and 24 hours post-dose were analyzed for metabolite profiles. Aliquots of urine were centrifuged at 14000 rpm in an Eppendorf Model 5415C centrifuge for 10 minutes. The supernatant was transferred to a fresh tube and analyzed for radioactivity content and by HPLC for metabolite profiling. Selected samples were also analyzed by LC/MS to characterize the radioactive peaks.
The stability of [14C]DVS in dog urine was determined. [14C]DVS (0.025 mg/mL, final concentration) was added to control dog urine and incubated in a shaking water bath set to 37° C. Aliquots (1 mL) were removed at 0, 1, 4, 8 and 24 hours. Samples were extracted as described above and radiopurity assayed by HPLC analysis.
Fecal homogenates collected up to 24 hours post-dose were analyzed for metabolite profiles. Aliquots of approximately 2 grams of fecal homogenate were transferred to a fresh tube, an equal volume of acetonitrile (v/w) was added, and the tube vortexed. Samples were then centrifuged at 14000 rpm in an Eppendorf Model 5415C centrifuge for 10 minutes. The supernatant was transferred to a clean tube. The residue was re-suspended with 1 mL acetonitrile and centrifuged as described above. The resulting supernatant was combined with the original supernatant and analyzed for radioactivity. The supernatants were then concentrated under a stream of nitrogen in a Turbo Vap to remove the acetonitrile. An aliquot of the aqueous residue was analyzed by HPLC for profiling. Selected samples were also analyzed by LC/MS to characterize the radioactive peaks.
Chromatographic analyses were performed with a Waters Alliance model 2690 HPLC system (Waters Corp., Milford, Mass.). It was equipped with a built-in autosampler and was in-line with a model 2487 tunable UV detector, set to monitor 225 nm, and a FloOne β Model 515 radioactivity flow detector (Perkin Elmer) with a 250 μL LQTR flow cell. The flow rate of Ultima Flow M scintillation fluid was 3 mL/min, providing a mixing ratio of scintillation cocktail to mobile phase of 3:1. Separation of the metabolite peaks was accomplished on a Phenomenex Luna C18(2) column, 250×4.6 mm, 5 micron (Phenomenex, Torrance, Calif.), using a linear gradient of two mobile phases, A and B. Mobile phase A was 10 mM ammonium acetate, pH 5.5, and mobile phase B was acetonitrile. The flow rate was 1 mL/min. The mobile phase was delivered as shown in Table 8.
An Agilent Model 1100 HPLC system (Agilent Technologies, Wilmington, Del.) including an autosampler and diode array UV detector was used for LC/MS analysis. The UV detector was set to monitor 200 to 400 nm. Separations were accomplished on a 5 micron Phenomenex Luna C18(2) column, 150×2 mm (Phenomenex). The column temperature was 25° C. The mobile phases and gradient program are listed in Table 2. For selected LC/MS analyses, radiochromatograms were acquired using a β-RAM model 3 radioactivity flow detector (IN/US Systems Inc., Tampa, Fla.) equipped with a solid scintillation flow cell.
The mass spectrometers used for metabolite characterization were a Micromass Q-TOF-2 quadrupole time-of-flight hybrid mass spectrometer (Micromass, Inc., Beverly, Mass.) and a Finnigan LCQ Deca ion trap mass spectrometer (ThermoFinnigan, San Jose, Calif.). The mass spectrometer was equipped with an electrospray ionization (ESI) interface and operated in the positive ionization mode. Settings for the mass spectrometers are listed in Table 9 and Table 10.
To confirm the site of glucuronidation of DVS, incubations were performed using dog liver microsomes. These incubations compared the glucuronidation of DVS to venlafaxine. Briefly, venlafaxine or DVS (100 μM) was incubated with dog liver microsomes (1 mg/mL) and MgCl2 (10 mM) in 0.1 M sodium/potassium phosphate buffer. Samples were pre-incubated for 2 minutes in a shaking water bath set to 37° C. Reactions were initiated by the addition of UDPGA (final concentration 1 mM). An additional set of incubations was performed for venlafaxine with UDPGA and an NADPH generating system. The total incubation volume was 500 μL and the length of incubation was 30 minutes. Reactions were stopped by the addition of 500 μL of acetonitrile and processed as described above. Samples were analyzed by LC/MS.
FloOne analytical software (version 3.65, Packard BioScience) was utilized to integrate the radioactive peaks. The computer program Microsoft Excele 97 was used to calculate means and standard deviations. MassLynx Software (version 3.5) was used to analyze the LC/MS data.
The radiochemical purity and specific activity of [14C]DVS (bulk compound), determined by HPLC with radiometric detection, were 99.3% and 209 μCi/mg (free base), respectively. The concentration, radiopurity and specific activity of [14C]O-desmethylvenlafaxine in the dosing solution were 10.3 mg/mL, 98.3% and 1.03 μCi/mg, respectively. Pre-, mid- and post-dose aliquots of the dosing solution had similar concentrations and purities (data not shown). The mean administered dose of [14C]DVS was 31.0±0.18 mg/kg (free base).
[14C]DVS was stable at 37° C. for up to 24 hours in control dog urine and control dog plasma. No significant degradation products were detected by radiochromatography at any of the time points up to and including 24 hours. Oxidation efficiency was determined by oxidation of 14C-Spec-Chec (Perkin Elmer), a standard of known radioactivity, and determined to be 99.1%. The concentrations of radioactivity in blood and plasma, and the blood to plasma partitioning for each time point are shown in Table 11. The mean plasma concentrations of total radioactivity in male dogs were 13.3, 16.9, 7.43, and 0.81 μg equivalents/mL at 1, 4, 8, and 24 hour post-dose, respectively. At each time point the blood to plasma ratio for radioactivity ranged between 0.51 and 0.64.
The average extraction efficiency of radioactivity from plasma was 87.6±10.1% (data not shown). A representative radiochromatogram of dog plasma collected 1 hour post-dose is shown in
U
U
P, U, F
P, U, F
aLC/MS retention time taken from data file GU_070202_0003.
bP: plasma; U: urine; F: feces. Bold face type indicates that the metabolite was also detected by radiochromatography.
Urine was the predominant route of excretion, with an average of 75% of the radioactive dose recovered in urine samples within 24 hours post-dose. The radioactivity concentrations detected in urine are shown in Table 13, as are the percent distribution of the radioactivity following radiochromatography. A representative radiochromatogram of dog urine collected 8-24 hours post-dose is shown in
aValues are expressed as percent of total peaks detected by radiochromatography, mean of 2 analyses.
bValues for % of dose include 0-8 and 8-24 hour time points, but 0-8 hour collection contained less than 0.1% of the dose.
Ten additional minor metabolites were characterized by LC/MS analysis of urine. These minor metabolites included M1-M6, a metabolite hydroxylated on the benzyl group (M9), N,O-didesmethylvenlafaxine (M10), N,N,O-tridesmethylvenlafaxine (M14), and N-oxide DV (Table 12).
The efficiency of extraction of radioactivity from the 0-24 hour fecal samples prior to radiochromatography was 76.8±6.2% (data not shown). The percent recovery in feces and the distribution of the radioactivity following radiochromatography are shown in Table 14. Only a small percentage of the radioactive dose (approximately 3%) was excreted in feces within 24 hours of dosing. A representative radiochromatogram of extracted dog feces collected 0-24 hours post-dose is shown in
aAt 24 hours post-dose there was no fecal sample for dog 7, so collection continued until 48 hours.
bValues are expressed as percent of total peaks detected by radiochromatography, average of 2 analyses.
Eight additional minor metabolites, not detected in the radiochromatograms, were characterized by LC/MS analysis of the fecal extracts. These metabolites included M1-M6, M7, and M9 (Table 12).
Mass spectra were obtained by LC/MS and LC/MS/MS analysis for DVS and its metabolites in dog plasma, urine, and feces. Structural characterization of the DVS metabolites in dog is summarized in Table 12. LC/MS data indicated metabolism of DVS to a glucuronide (M7), N-desmethyl DVS (M10), and mono-oxidation products. The mass spectral characterization of DVS and 14 metabolites is discussed below.
The mass spectral characteristics of DVS standard were examined for comparison with metabolites. In the LC/MS spectrum of DVS, a protonated molecular ion, [M+H]+ was observed at m/z 264.
Metabolites M1, M2, M3, M4, M5 and M6 (hydroxy DV compounds) produced a [M+H]+ at m/z 280, which was 16 Da larger than DVS and suggested hydroxylation or N-oxidation.
Metabolite M7 (O-desmethylvenlafaxine O-glucuronide, DV glucuronide) The [M+H]+ for this metabolite was observed at m/z 440, which indicated a molecular weight of 439.
Metabolite M9 produced [M+H]+ at m/z 280, which was 16 Da larger than DVS and suggested hydroxylation or N-oxidation.
The [M+H]+ for M10 was observed at m/z 250.
The [M+H]+ for M11a, M11b, M11c and M12 were observed at m/z 456, which indicated a molecular weight of 455.
Metabolite M13 (N,O-didesmethylvenlafaxine O-glucuronide). The [M+H]+ for this metabolite was observed at m/z 426, which indicated a molecular weight of 425.
Metabolite M14 produced [M+H]+ at m/z 236.
The [M+H]+ for this DVS related component was observed at m/z 280, which indicated hydroxylation or N-oxidation.
The 2-hydroxy-DV compounds of the invention may be produced using the following method. 4-(Dimethylcarbamoylmethyl)phenol in dimethylformamide
(DMF) is treated with K2CO3 followed by benzyl bromide. The mixture is stirred at room temperature followed by heating at 60° C. for 1 hour. The mixture is concentrated to remove DMF, diluted with EtOAc and washed with water. Dry MgSO4 is added, the mixture filtered and concentrated to low volume. Hexane is added to precipitate the ketal intermediate product. Solids are collected via filtration and dryed.
A solution of the 2-benzyloxy-cyclohexanone in 100 mL THF/50 mL MeOH is treated with acid (e.g., HCl), then stirred at room temperature. The reaction is quenched with saturated K2CO3, extracted with EtOAc and concentrated to an oil. Product is crystallized from hot EtOAc/hexanes to provide the ketone intermediate as shown in
A solution of the ketone in THF was added to a suspension of lithium aluminum hydride (LAH) pellets in THF at −78° C. The mixture is warmed to room temperature and stirred for at least 3 hours. The reaction is quenched with MeOH followed by 10% NaOH and stirred for at least 3 hours. The solid are removed by filtration, followed by a wash (e.g., with THF), and concentrated to give a solid. The resulting solid is recrystallized from EtOAc/hexanes to provide the corresponding benzyl ether.
Both benzyl protecting groups may be removed by stirring with Pd/C in 100 mL of ethanol, and hydrogenating under pressure overnight. The solid is purified by filtration followed by an ethanol wash. Solid is concentrated and crystallized from EtOAc/hexane to give the final product.
The 2-hydroxy DV glucoronide compounds may be synthesized as follows. To a solution of 2-hydroxy DV (1.0 g, 3.6 mmol) and 2.05 g (4.3 mmol) of the trichloroimidate in methylene chloride (15 mL) is added BF3OET2 (0.54 mL, 4.4 mmol) dropwise over a 5 min period. The reaction is stirred overnight under nitrogen atmosphere. Then the reaction mixture is poured into NaHCO3 (sat) and extracted with methylene chloride. The organic layer is separated, dried and concentrated in vacuo. The crude residue is passed through a short silica column, elution with methylene chloride-methanol. The filtrate is concentrated to provide the protected 2-hydroxy DVO-glucuronide (see
The protected 2-hydroxy DV glucuronide (the tri acetyl methyl ester) (1.0 g, 1.7 mmol) is taken up in a mixture of dioxane-MeOH—H2O (2:1:1) 8 mL and LiOH (0.4 g, 17 mmol) is added and the resulting solution is heated to 60° C. for 1 hr. The reaction mixture is then cooled and diluted with acetic acid. The mixture is concentrated in vacuo and the residue may be purified on silica with methylene chloride-methanol to provide 2-hydroxy DV glucuronide.
N-oxide DV was prepared using a chemical synthesis strategy as follows. To prepare N-oxide DV I shown in
The N-oxide DV II shown in
The compound is a white solid (1.03 g, 97.3%). Mp. 175-176° C. 1H NMR (DMSO-d6), δ (ppm): 0.68-1.64 (m, 10H), 2.95 (s, 3H), 3.14 (s, 3H), 3.19 (d, J=5.7 Hz, 1H), 3.54 (d, J=12.7 Hz, 1H), 3.89 (dd, J=7.5 Hz and 7.3 Hz, 1H), 6.67 (d, J=8.4 Hz, 2H), 6.98 (d, J=8.4 Hz, 2H), 9.51 (s, 1H); (M+H)+ 280; (M−H)− 278; Anal. Calculated for C16H25NO3: C, 68.79; H, 9.02; N, 5.01; Found C, 60.62; H, 7.84; N, 4.02; Analytical HPLC (5-95% Acetonitrile/water); 98.0% at 210 nM, 99.0% at 230 nM; Optical rotation; −15.49 (corrected for chloroform impurity).
The N-oxide of (R)-4-[2-Dimethylamino-1-(1-hydroxy-cyclohexyl)-ethyl]-phenol (III) was prepared as compounds I and II (see
The compounds of the present invention may be tested for biological activity using receptor assay binding studies. These studies have been described in the following publications, and are also available from Novascreen, Hanover, Md. The receptor binding assays that may be used include, but are not limited to: adrenergic α-2A (human) binding assay (D. B. Bylund et al, J Pharmacol & Exp Ther, 245(2):600-607 (1988); J A Totaro et al, Life Sciences, 44:459-467 (1989)); dopamine transporter binding assay (Madras et al, Mol. Pharmacol., 36:518-524; J J Javitch et al, Mol Pharmacol, 26:35-44 (1984)); histamine H1 binding assay (Chang, et al., J Neurochem, 32:1658-1663 (1979); J I Martinez-Mir, et al., Brain Res, 526:322-327 (1990); E E J Haaksma, et al, Pharmacol Ther, 47:73-104 (1990)); imidazoline binding assay (C M Brown et al, Brit. J Pharmacol, 99(4):803-809 (1990); muscarinic M5 (human recombinant) binding assay (N J Buckley et al, Mol Pharmacol, 35:469-476 (1989);); norepinephrine transporter (human recombinant) binding assay (R. Raisman, et al., Eur J Pharmacol, 78:345-351 (1982); S. Z. Raisman, et al, Eur J Pharmacol, 72:423 (1981)); serotonin transporter (human) binding assay (R J D'Amato, et al, J Pharmacol & Exp Ther, 242:364-371 (1987); N L Brown et al, Eur J Pharmacol, 123:161-165 (1986)). The cellular/functional assays include the norepinephrine transport (NET-T) human (A. Galli, et al., J Exp Biol, 198:2197-2212 (1995); and the serotonin transport (Human) assay (D'Amato et al, cited above and N L Brown et al, Eur J Pharmacol, 123:161-165 (1986)). The results may be measured as % inhibition of the receptor.
The compounds of the present invention may be evaluated in microdialysis studies, for example, in male Sprague-Dawley rats. M T Taber et al, “Differential effects of coadministration of fluoxetine and WAY-100635 on serotonergic neurotransmission in vivo: sensitivity to sequence of injections,” Synapse, 38(1): 17-26 (October 2000). This technique can capture the neurochemical effects of compounds in the brains of freely-moving rodents. The effects may be studied in the rat dorsal lateral frontal cortex, a brain region thought to be involved in etiology and/or treatment of depression. To see whether any effects on serotonin could be observed, a compound of the present invention (at a dose of 30 mg/kg, sc) may be tested in combination with the selective 5-HT1A antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide. The rationale for doing this is to block the somatodendritic 5-HT1A autoreceptors regulating 5-HT release. This eliminates the need to perform a chronic (14 day) neurochemical study with the compound alone to desensitize the 5-HT1A receptors. The conditions of a suitable study are listed below:
Animal: Male Sprague-Dawley rats (280-350 g)
Under these conditions, in vivo neurochemical effects may be observed. The in vivo neurochemical effects of combinations of other SNRIs and SSRIs, like venlafaxine and fluoxetine, with 5-HT1A antagonism may be observed for comparison.
The specification is most thoroughly understood in light of the teachings of the references cited within the specification. The embodiments within the specification provide an illustration of embodiments of the invention and should not be construed to limit the scope of the invention. The skilled artisan readily recognizes that many other embodiments are encompassed by the invention. All publications and patents cited in this disclosure are incorporated by reference in their entirety. To the extent the material incorporated by reference contradicts or is inconsistent with this specification, the specification will supercede any such material. The citation of any references herein is not an admission that such references are prior art to the present invention.
Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification, including claims, are to be understood as being modified in all instances by the term “about.” Accordingly, unless otherwise indicated to the contrary, the numerical parameters are approximations and may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.
Unless otherwise indicated, the term “at least” preceding a series of elements is to be understood to refer to every element in the series. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Additional embodiments of the instant invention include the following desvenlafaxine metabolites:
| Number | Date | Country | |
|---|---|---|---|
| 60854063 | Oct 2006 | US |
